Recombinant and Synthetic Cancer Vaccines PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Recombinant and Synthetic Cancer Vaccines PDF full book. Access full book title Recombinant and Synthetic Cancer Vaccines by Willem Willie Overwijk. Download full books in PDF and EPUB format.
Author: Willem Willie Overwijk
Publisher:
ISBN:
Category :
Languages : en
Pages : 288
Get Book Here
Book Description
Author: Willem Willie Overwijk
Publisher:
ISBN:
Category :
Languages : en
Pages : 288
Get Book Here
Book Description
Author: Jean-Francois Jeannin
Publisher: Springer Science & Business Media
ISBN: 1441916032
Category : Medical
Languages : en
Pages : 145
Get Book Here
Book Description
Cancer remains a major challenge for modern society. Not only does cancer rank among the first three causes of mortality in most population groups but also the therapeutic options available for most tumor types are limited. The existing ones have limited efficacy, lack specificity and their administration carry major side effects. Hence the urgent need for novel cancer therapies. One of the most promising avenues in research is the use of specific immunotherapy. The notion that the immune system may have important anti-tumor effects has been around for more than a century now. Every major progress in microbiology and immunology has been immediately followed by attempts to apply the new knowledge to the treatment of cancer. Progress has reached a point where it is well established that most cancer patients mount specific T cell responses against their tumors. The molecular identity of the antigens recognized by anti-tumor T cells has been elucidated and several hundreds of tumor-derived antigenic peptides have been discovered. Upon recognition of such peptides presented by self MHC molecules, both CD8 and CD4 T cells are activated, expand to high numbers and differentiate into effective anti-tumor agents. CD8 T cells directly destroy tumor cells and can cause even large tumors to completely regress in experimental mouse models. These observations have spurred intense research activity aimed at designing and testing cancer vaccines. Over 100 years ago Coley successfully used intratumoral injection of killed bacteria to treat sarcomas. The important anti-tumor effects observed in a fraction of these patients fueled major research efforts. These led to major discoveries in the 80s and the 90s. It turns out that bacterial lipopolysaccharides stimulate the production of massive amounts of a cytokine still known today as tumor necrosis factor (TNF-a). They do so by engagement of a rather complex set of interactions culminating in the ligation of a Toll-like receptor, TLR -4. Ensuing signaling through this receptor initiates potent innate immune responses. Unfortunately the clinical use of both TNF-a and LPS can not be generalized due to their very narrow therapeutic margin. Importantly, synthetic Lipid A analogs have been identified that retain useful bioactivity and yet possess only mild toxicity. The relatively large body of information accumulated thus far on the molecular and cellular interactions set in motion by administration of LPS as well as by the synthetic lipid A analogs allow to place this family of bacterially-derived molecules at the crossroads between innate and adaptive immunity. By virtue of this key position, the therapeutic applications being pursued aim at using these compounds either as direct anti-tumor agents or as vaccine adjuvants. The clinical experience acquired so far on these two avenues is asymmetric. Few clinical trials using Lipid A analogs as single anti-cancer agents involving less than 100 patients with advanced cancer have been reported. In contrast, lipid A has been tested in over 300,000 individuals in various vaccines trials, including therapeutic cancer vaccines. Clearly most of the work needed to develop lipid A as effective anti-cancer agents and/or as vaccine adjuvant lies ahead in the near future. This book is a timely contribution and provides a much needed up-to-date overview of the chemical, biological and physiological aspects of lipid A. It should be a beacon to all those involved in this field of research.
Author: Luigi Buonaguro
Publisher: Academic Press
ISBN: 0128239026
Category : Science
Languages : en
Pages : 273
Get Book Here
Book Description
Cancer Vaccines as Immunotherapy of Cancer provides extensive and state-of-the-art information about the meaning, relevance and limitation of therapeutic cancer vaccines. It covers all the aspects involved in the vaccine research and development (identification of optimal target antigens, formulations, delivery strategies, adjuvants among others) as well as their use in combination with other immunomodulatory approaches. The book discusses topics such as identification of tumor associated and specific antigens, proteogenomic for identification of novel target tumor antigens, antigen-specific T cells, and Peptide and RNA based vaccines. Additionally, it covers oncolytic viruses for antigen delivery, cancer vaccine targeting viral antigens and combinatorial immunotherapy strategies. Written by leading experts worldwide, this is a valuable resource for cancer researchers, oncologists and members of biomedical field who wants to understand in depth the recent findings in the field of cancer vaccines. Describes the state-of-the-art of the research and development of therapeutic cancer vaccines Presents detailed diagrams to help the reader understand the functionality of each type of vaccine discussed Encompasses recent findings in the field through chapters written by leading experts worldwide
Author: Adrian Bot
Publisher: CRC Press
ISBN: 1841848301
Category : Medical
Languages : en
Pages : 294
Get Book Here
Book Description
Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: From Research to Clinical Practice is the first text in the field to bring immunotherapy treatments
Author: W. Martin Kast
Publisher: CRC Press
ISBN: 1498713238
Category : Science
Languages : en
Pages : 231
Get Book Here
Book Description
The field of peptide based cancer vaccines has evolved tremendously in the last decade of this century. The exploration on how to apply the peptide knowledge for vaccination purposes began when it was demonstrated that these peptides after being mixed into adjuvants actually induced T cell responses that could prevent virus infections and tumor gro
Author: Jeffrey Schlom
Publisher: Elsevier Inc. Chapters
ISBN: 0128059168
Category : Medical
Languages : en
Pages : 51
Get Book Here
Book Description
This article reviews progress made in the design and development of recombinant poxviral-based vaccines that express transgenes for tumor-associated antigens (TAAs) and human T-cell co-stimulatory molecules (designated TRICOM). The TRICOM vaccine platform consists of priming with a recombinant vaccinia (rV-) vector and multiple boosts with a replication defective fowlpox (rF-) vector. The rV, rF-PSA-TRICOM (PROSTVAC) has demonstrated survival benefit in randomized trials. rV, rF-CEA-MUC1-TRICOM (PANVAC) has demonstrated evidence of benefit in patients with colorectal, breast and ovarian cancers. Preclinical studies with TRICOM-based vaccines have demonstrated their ability to be used in combination with anti-CTLA4 monoclonal antibody, radiation, chemotherapeutics, and small molecule targeted therapies to enhance vaccine-mediated immune responses and antitumor activity. Randomized clinical studies have been completed, are ongoing, and are planned employing several of these TRICOM vaccine combination therapies. The importance of trial design in terms of patient population and clinical trial endpoint has been demonstrated in these studies.
Author: Michael A. Morse
Publisher: Springer Science & Business Media
ISBN: 1592596800
Category : Medical
Languages : en
Pages : 585
Get Book Here
Book Description
An authoritative survey of the scientific background for therapeutic cancer vaccines, the challenges to their development, and their current uses in treating cancer. The authors examine the basic issues that effect all vaccines (such as immune adjuvants and prime-boost strategies), describe the methods for antigen discovery, and review the preclinical development phases for each major vaccine strategy. They also spell out the clinical results for cancer vaccines now beginning to be used in the treatment of many common cancers.
Author: Peter L. Stern
Publisher: Cambridge University Press
ISBN: 9780521622639
Category : Medical
Languages : en
Pages : 304
Get Book Here
Book Description
Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 15
Get Book Here
Book Description
ErbB-2 is a tumor associated antigen. Vaccination with wild-type ErbB-2 DNA induces effective anti-tumor immunity which includes a strong anti-ErbB-2 antibody response. To activate specific components of the immune response, DNA vaccines were constructed which direct recombinant ErbB-2 to the subcellular compartments of antigen processing and presentation. To induce ErbB-2 specific CTL, a recombinant cytoplasmic ErbB-2 which lacks kinase activity was constructed. CytE2 localizes in the cytoplasm and is rapidly degraded by the proteosome. Vaccination with cytE2 alone does not protect against an ErbB-2 expressing tumor. This may be due to a lack of CD4 T cell induction. To activate or replace ErbB-2 specific CD4 T cells, co-vaccination of cytE2A with cytokine genes was examined. Co-vaccination of cytE2A with either IL-2 or GM-CSF genes induced anti-ErbB-2 CTL and an effective anti-tumor immune response. To induce ErbB-2 specific CD4 T cells, a recombinant ErbB-2 which is targeted to the lysosome for MHC class II processing and presentation was constructed. Co-vaccination with E2-Lamp + GM-CSF induced effective anti-tumor immunity. This study demonstrates the feasibility of eliciting individual effector mechanisms by vaccination with targeted DNA constructs and protection against ErbB-2 expressing tumors without antibody activity.
Author: Daan J. A. Crommelin
Publisher: CRC Press
ISBN: 9780415285018
Category : Medical
Languages : en
Pages : 456
Get Book Here
Book Description
The field of pharmaceutical biotechnology is evolving rapidly. A whole new arsenal of protein pharmaceuticals is being produced by recombinant techniques for cancer, viral infections, cardiovascular and hereditary disorders, and other diseases. In addition, scientists are confronted with new technologies such as polymerase chain reactions, combinatorial chemistry and gene therapy. This introductory textbook provides extensive coverage of both the basic science and the applications of biotechnology-produced pharmaceuticals, with special emphasis on their clinical use. Pharmaceutical Biotechnology serves as a complete one-stop source for undergraduate pharmacists, and it is valuable for researchers and professionals in the pharmaceutical industry as well.
